Hangzhou Cancer Hospital Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2016
NCT03011255
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Shixiu Wu

Active Ingredients

Drugs in Phase 2 Trials (2)

esophageal cancer peptide specific ctl (1 trial)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Digestive System Diseases (Phase 2)

Esophageal Diseases (Phase 2)

Esophageal Neoplasms (Phase 2)

Gastrointestinal Diseases (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2